结论：应改进液体口服制剂分剂量包装。
CONCLUSION: It should to improve the distributing dose package of liquid oral medicines.
该口服制剂崩解及溶出更快、稳定性更高。
The oral preparation has the characteristics of faster disintegration and dissolution, and higher stability.
目的：探讨液体口服制剂分剂量的准确性。
OBJECTIVE: To study the accuracy of liquid oral medicines in distributing dose.
目的：了解青霉素类口服制剂的安全性问题。
Objective: To understand the safety of oral penicillins agents.
本发明涉及一种紫杉醇类双层软胶囊口服制剂药物。
The invention relates to a taxol double-layer soft capsule oral preparation medicament.
本发明可按常规口服制剂的生产方法制成口服片剂。
The drug composite can be produced to be oral tablet according to the production methods of conventional oral intake preparations.
它可制成临床或药学上可接受的任一剂型，优选口服制剂。
The drug can be prepared into any preparation form acceptable for clinic or pharmacy, while oral preparation is preferential.
FP的口服制剂中，大多存在溶出难和生物利用度低的问题。
Most oral dosage forms of FP had low bioavailability because FP could hardly dissolve.
本发明涉及一种以中药为主要原料的中药口服制剂的制备方法。
The invention relates to a preparation method for a traditional Chinese medicine oral preparation with traditional Chinese medicines as main materials.
本发明涉及一种由天然植物制成的、具有治疗效果的复方口服制剂。
The invention relates to a compound oral preparation which is made from natural plants and has treatment effect.
目的研制一种生物利用度高适合餐后血糖变化模式的胰岛素口服制剂。
Objective To manufacture a high bioavailability oral insulin that fit the blood glucose change after meals.
靛玉红衍生物与药学上允许的辅料加工成片剂、胶囊剂等口服制剂。
The indirubin derivative and pharmaceutically acceptable supplementary material may be prepared into tablet, capsule or other oral preparation.
从生物药剂学的角度设计了“半仿生提取法”制备中药口服制剂的新工艺。
In the light of biopharmacy, the present new technology to extract oral preparations of Chimese traditional medicinal by semi-bionic method was designed.
本发明公开了一种治疗咳嗽的口服制剂及其制备方法，属于药品技术领域。
The invention discloses an oral preparation for treating cough and a preparing method thereof, which belongs to medicine technology art.
该药物组合物可以制成各种药学上可接受的剂型，优选注射剂和口服制剂。
The medicine composition may be prepared into different pharmaceutically acceptable forms, preferably injection and oral preparation.
该药物组合物可制成临床或药学上可接受的剂型，优选注射剂或口服制剂。
The medicine composition may be prepared into different pharmaceutically acceptable forms, preferably injection and orally taken preparation.
本发明是在西替利嗪中，配合作为稳定剂的碱性化合物形成口服制剂组合物。
The invention discloses an oral preparation composition prepared by being matched with an alkaline compound taken as a stabilizing agent in cetirizine.
本发明中药组合物可按照常规的中药制剂方法制备成任何一种常用口服制剂。
The traditional Chinese medicine composition can be prepared into any commonly used oral preparation according to a conventional traditional Chinese medicine preparation method.
该研究旨在比较这两种药的口服制剂治疗早产儿动脉导管未闭的疗效和安全性。
This study aimed to examine and compare the efficacy and safety of oral ibuprofen and oral indomethacin for the treatment of PDA in preterm infants.
这提示1,25二羟基维生素d 3口服制剂的浓缩剂型，将有利于其吸收利用。
It is indicates that the concentrated capsule of 1, 25-dihydroxyvitamin D3 oral preparation would be in favor of absorption and utilization.
埃索美拉唑缓释剂(BE)是由碳酸氢钠包被非肠溶性埃索美拉唑组成的口服制剂。
Buffered esomeprazole (BE) is an oral preparation consisting of an inner core of non-enteric-coated esomeprazole with a shell of sodium bicarbonate.
胃肠道生物粘附给药系统(GBDDS)是现代生物粘附技术在口服制剂中的运用。
Gastrointestinal bioadhesion drug delivery system (GBDDS) can be considered as an application of bioadhesion technology to the oral drug delivery system.
外用中药制剂因剂型、用药方法等和常用的口服制剂以及静脉制剂相比有其特殊性。
The traditional medications for external use have particularities compared with the common oral administration and the injection.
目的：为避免酮洛芬口服制剂对胃肠道的刺激作用，制备酮洛芬凝胶替代其口服制剂。
OBJECTIVE: to avoid the irritation of oral ketoprofen in gastrointestinal tract, the ketoprofen gel was prepared.
这些给药系统的口服制剂的组成和与药物相关的生物药剂学方面已经进行了广泛的研究。
The formulation and drug-related biopharmaceutical aspects of these systems that govern oral absorption have been widely studied.
2015年进行辰欣药业CGMP口服制剂自动配料及物料管理系统的研发、验证工作。
2014-2015, engaged in research, development and validation of automatic burdening and material management system for CGMP oral preparation in Cisen Pharmaceutical Co. , Ltd.
另外，通过制成口服制剂、注射剂，能够全身给药， 故作为深部真菌症的治疗药有用。
Also, this composition is useful as a therapeutic agent for deep mycoses because systemic administration is possible by applying it to an oral agent or an injection.
本发明涉及一种非那雄胺口服制剂及其制备方法，具体是由主药非那雄胺和药用辅料组成。
The invention relates to a non-finasteride oral preparation and preparation method, specifically which consists of main drug non-finasteride and medicinal findings.
中国奥星医药公司最近报道完成了可待因磷酸盐的注册试验。可待因是一种可治疗急性中度到重度咳嗽的口服制剂。
China Aoxing Pharmaceutical Company reported that it has completed the registration trial of Codeine Phosphate, an oral solution that treats acute moderate to severe cough.
中国奥星医药公司最近报道完成了可待因磷酸盐的注册试验。可待因是一种可治疗急性中度到重度咳嗽的口服制剂。
China Aoxing Pharmaceutical Company reported that it has completed the registration trial of Codeine Phosphate, an oral solution that treats acute moderate to severe cough.
应用推荐